By Ben Butkus

Enigma Diagnostics said this week that it has commenced clinical trials in the US for its first diagnostic assay, a real-time PCR-based point-of-care test for influenza A and B.

Enigma will go it alone, however, as the company confirmed that it is no longer commercializing its test, the Enigma ML Influenza A/B detection assay, in partnership with GlaxoSmithKline as was previously reported.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.